vorolanib

Vorolanib is a next-generation, orally administered small-molecule multi–tyrosine kinase inhibitor that targets all isoforms of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). By inhibiting these receptor tyrosine kinases, vorolanib blocks tumor angiogenesis and cell proliferation, leading to tumor cell death. It has been developed for both oncology indications—such as renal cell carcinoma and various solid tumors—and ophthalmic diseases like wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), where it is formulated as a sustained-release intravitreal implant (EYP 1901). Vorolanib has demonstrated efficacy in combination with other agents such as everolimus or immune checkpoint inhibitors in cancer trials, and its unique mechanism offers potential advantages over traditional anti–VEGF therapies in eye disease[1][3][4][5][6].

Brand names

vorolanib

Other names

Fumena